InvestorsHub Logo
icon url

coinstarz

05/23/06 5:45 PM

#1771 RE: Kevin40 #1769

Takeover is a long shot IMO. I remembered I talked to someone last year that Insmed will sell the company in 2010-2012 when they reach 2-3 Billion market cap. That is what Dr. Allan and Sommer are doing. I try to not think about takeover but iPlex launch now.
icon url

theonlyslacker

05/23/06 7:53 PM

#1775 RE: Kevin40 #1769

blissonmoon,

If you read further the poster who mentioned PFE and DNA recanted and said he was "kidding" (not funny, I know). There is a poison pill from way back that makes a hostile takeover highly unlikely. Based on the apparent view of the current management they have always had a propensity to go it alone in hopes of reaping all the rewards (either a very deep belief in the value of the drug or a stubborness. I like the first story best). Partnership is a possibility on some of the indications IMHO.

The $22 target a few years ago was before a 1 for 4 reverse split and prior to the failure of INS-1 in diabetes trials. INS 1 was Insmed's original drug candidate. Somatokine(now named IPlex) was acquired when Insmed purchased Celtrix a few years ago. This stock has been in the low $.30 range in October 2002 just after the failure of INS-1.

One might question whether I have been here too long, huh? Always believed in the science, have received one hell of an education, and made a little money along the way.

GLTA! Slacker